Comparison of patients with isolated cutaneous lupus erythematosus versus systemic lupus erythematosus with cutaneous lupus erythematosus as the sole clinical feature : A monocentric study of 149 patients
Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Cutaneous lupus erythematosus (CLE) may present as an isolated entity or be classified as Systemic lupus erythematosus (SLE) by the presence of laboratory abnormalities, including cytopenia, low complement levels, and/or autoantibodies (CLE with laboratory SLE).
OBJECTIVE: To compare isolated CLE and CLE with laboratory SLE and to validate an existing 3-item score with age < 25 years (1 point), phototypes V to VI (1 point), antinuclear antibodies ≥ 1:320 (5 points) to predict the risk of progression from CLE to severe SLE (sSLE).
METHODS: Monocentric cohort study including consecutive patients with CLE. CLE with laboratory SLE was defined by 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for SLE score of ≥10 points at baseline with CLE as the sole clinical feature.
RESULTS: Of the 149 patients with CLE, 20 had CLE with laboratory SLE. The median follow-up duration was 11.3 years (IQR: 5.1-20.5). Ten patients (7%) had sSLE developed. In survival analysis, the risk of progression to sSLE was higher among CLE with laboratory SLE (hazard ratio = 6.69; 95% CI: 1.93-23.14, P < .001) compared to isolated CLE. In both groups, none of the patients with a risk score ≤ 2 had sSLE developed.
LIMITATIONS: Monocentric study with a limited number of patients.
CONCLUSIONS: CLE with laboratory patients with SLE have a higher risk of progression to sSLE than isolated CLE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - (2024) vom: 01. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Masseran, Clémence [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cutaneous lupus erythematosus |
|---|
| Anmerkungen: |
Date Revised 25.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jaad.2024.01.041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367912910 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367912910 | ||
| 003 | DE-627 | ||
| 005 | 20240229151617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2024.01.041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1305.xml |
| 035 | |a (DE-627)NLM367912910 | ||
| 035 | |a (NLM)38301924 | ||
| 035 | |a (PII)S0190-9622(24)00158-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Masseran, Clémence |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of patients with isolated cutaneous lupus erythematosus versus systemic lupus erythematosus with cutaneous lupus erythematosus as the sole clinical feature |b A monocentric study of 149 patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Cutaneous lupus erythematosus (CLE) may present as an isolated entity or be classified as Systemic lupus erythematosus (SLE) by the presence of laboratory abnormalities, including cytopenia, low complement levels, and/or autoantibodies (CLE with laboratory SLE) | ||
| 520 | |a OBJECTIVE: To compare isolated CLE and CLE with laboratory SLE and to validate an existing 3-item score with age < 25 years (1 point), phototypes V to VI (1 point), antinuclear antibodies ≥ 1:320 (5 points) to predict the risk of progression from CLE to severe SLE (sSLE) | ||
| 520 | |a METHODS: Monocentric cohort study including consecutive patients with CLE. CLE with laboratory SLE was defined by 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for SLE score of ≥10 points at baseline with CLE as the sole clinical feature | ||
| 520 | |a RESULTS: Of the 149 patients with CLE, 20 had CLE with laboratory SLE. The median follow-up duration was 11.3 years (IQR: 5.1-20.5). Ten patients (7%) had sSLE developed. In survival analysis, the risk of progression to sSLE was higher among CLE with laboratory SLE (hazard ratio = 6.69; 95% CI: 1.93-23.14, P < .001) compared to isolated CLE. In both groups, none of the patients with a risk score ≤ 2 had sSLE developed | ||
| 520 | |a LIMITATIONS: Monocentric study with a limited number of patients | ||
| 520 | |a CONCLUSIONS: CLE with laboratory patients with SLE have a higher risk of progression to sSLE than isolated CLE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cutaneous lupus erythematosus | |
| 650 | 4 | |a evolution | |
| 650 | 4 | |a progression | |
| 650 | 4 | |a score | |
| 650 | 4 | |a severe systemic lupus erythematosus | |
| 650 | 4 | |a systemic lupus erythematosus | |
| 700 | 1 | |a Perray, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Murat de Montai, Quitterie |e verfasserin |4 aut | |
| 700 | 1 | |a Mathian, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Teboul, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Francès, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaud, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Costedoat-Chalumeau, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Amoura, Zahir |e verfasserin |4 aut | |
| 700 | 1 | |a Courvoisier, Delphine S |e verfasserin |4 aut | |
| 700 | 1 | |a Barbaud, Annick |e verfasserin |4 aut | |
| 700 | 1 | |a Chasset, François |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g (2024) vom: 01. Feb. |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2024.01.041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 02 | ||